Answer
Whether atezolizumab passes into human milk is unknown, but it is expected in first milk and at low levels afterwards; infant risk cannot be excluded, so breastfeeding or Tecentriq therapy must be discontinued after weighing breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Tecentriq 840 mg and 1,200 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 44Document updated
Sources checked